Professional
Added to YB: 2025-05-07
Pitch date: 2025-03-31
ACLX [neutral]
Arcellx, Inc.
+9.63%
current return
Author Info
No bio for this author
Company Info
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
Market Cap
$5.2B
Pitch Price
$65.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-20.91
P/E
-22.87
EV/Sales
130.33
Sector
Biotechnology
Category
growth
Baron Health Care Fund Portfolio Holding: Arcellx, Inc.
ACLX (holding update): Cell therapy for multiple myeloma, lead drug anito-cel with Gilead. Stock fell on safety fears despite promising data showing efficacy matching CARVYKTI with fewer side effects. Mid-year trial updates expected with potential 2H 2026 approval. Differentiated safety profile should be validated by new data.
Read full article (1 min)